UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Financial Data and Key Metrics Changes - For the full year 2020, total revenues were $133.2 million, a 5% increase from $127.2 million in 2019, aligning with guidance of $132 million to $137 million [6][20] - Gross profit for Q4 2020 was $10.2 million with a gross margin of 33%, down from $12.1 million and 38% in Q4 2019 [21] - Net income for Q4 2020 was $1.6 million or $0.04 per share, compared to $5.4 million or $0.13 per share in Q4 2019 [23] Business Line Data and Key Metrics Changes - The distribution product segment margins were negatively impacted in 2020 due to a shift in product mix [21] - The company plans to expand its biosimilar product portfolio, expecting potential sales of $25 million to $35 million annually from nine biosimilar products [15][29] Market Data and Key Metrics Changes - The company is focused on increasing market share for KEDRAB in the U.S. and expanding GLASSIA sales in ex-U.S. markets [18] - The company anticipates generating royalties from GLASSIA projected to be in the range of $10 million to $20 million per year starting in 2022 [18] Company Strategy and Development Direction - Kamada aims to become a fully-integrated specialty plasma company by expanding its plasma-derived product business and enhancing manufacturing capabilities [8][10] - The company is developing its pipeline, focusing on the Phase III InnovAATe clinical trial for inhaled AAT and exploring new strategic business development opportunities [9][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's fundamentals despite challenges posed by the COVID-19 pandemic, highlighting a strong balance sheet and multiple growth catalysts [6][56] - The company expects reduced revenues and profitability in 2021 due to the transition of GLASSIA manufacturing and ongoing uncertainties from COVID-19 [24] Other Important Information - As of December 31, 2020, the company had cash balances of $109.3 million, up from $73.9 million a year earlier [24] - The company has initiated a supply of its COVID-19 IgG product to the Israeli Ministry of Health, expected to generate approximately $3.5 million in revenue [12] Q&A Session Summary Question: Can you describe the approval pathway for biosimilars? - Management indicated that approvals will primarily rely on EMA, with the Israeli Ministry of Health typically approving based on EMA or U.S. approval [28] Question: What is the annual collection capacity at Beaumont today? - Management did not disclose specific volumes but emphasized plans to maximize capacity and focus on hyperimmune plasma collection [34] Question: What should we anticipate for R&D spend in 2021? - Management expects R&D spend to remain similar to 2020, with recruitment timelines impacted by COVID-19 [43] Question: How should we think about product revenue in 2021? - Management did not provide specific guidance for 2021 due to COVID-19 uncertainties but indicated steady growth in the Israel Distribution business [50]

Kamada Ltd. (NASDAQ:KMDA) Q3 2020 Results Earnings Conference Call November 11, 2020 8:30 AM ET Company Participants Bob Yedid - LifeSci Advisors Amir London - CEO Chaime Orlev - CFO Conference Call Participants Raj Denhoy - Jefferies Operator Greetings and welcome to the Kamada Limited Third Quarter 2020 Earnings Call. At this time, all participants are in a listen-only mode, a question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder this conference is being re ...

Kamada Ltd. (NASDAQ:KMDA) Q2 2020 Earnings Conference Call August 12, 2020 8:30 AM ET Company Participants Troy Williams – LifeSci Advisors Amir London – Chief Executive Officer Chaime Orlev – Chief Financial Officer Conference Call Participants Raj Denhoy – Jefferies Keay Nakae – Chardan Operator Welcome to the Kamada Limited Second Quarter 2020 Earnings Conference Call. As a reminder, all participants are in listen-only mode and the conference is being recorded. After the presentation, there will an oppor ...

Kamada Ltd (NASDAQ:KMDA) Q1 2020 Results Conference Call May 18, 2020 8:30 AM ET Company Participants Bob Yedid - LifeSci Advisors Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Raj Denhoy - Jefferies Keay Nakae - Chardan Capital Markets Operator Greetings, welcome to the Kamada Limited First Quarter 2020 Earnings Conference Call. At this time, all participants will be in a listen-only mode. A brief question-and-answer session will follow the formal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Kamada Ltd. (NASDAQ:KMDA) Q3 2019 Results Earnings Conference Call November 14, 2019 8:30 AM ET Company Participants Bob Yedid - Investor Relations, LifeSci Advisors, LLC Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Briana Warschun - Jefferies Keay Nakae - Chardan Capital Markets Operator Greetings. And welcome to the Kamada Ltd. Third Quarter 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-a ...

Kamada Ltd. (NASDAQ:KMDA) Q2 2019 Results Earnings Conference Call August 6, 2019 8:30 AM ET Company Participants Paul Arndt - Investor Relations, Managing Director at LifeSci Advisors Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Keay Nakae - Chardan Capital Markets Operator Greetings and welcome to Kamada Ltd. second quarter 2019 earnings call. At this time, all participants are in a listen-only mode. A questions-and-answer session will follow th ...

Kamada Ltd. (NASDAQ:KMDA) Q1 2019 Earnings Conference Call May 14, 2019 8:30 AM ET Company Participants Bob Yedid - LifeSci Advisors, LLC Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Raj Denhoy - Jefferies Operator Greetings and welcome to the Kamada's First Quarter 2019 Earnings Call. [Operator Instructions] Please note this conference is being recorded. I'd now turn the conference over to your host today Mr. Bob Yedid with LifeSci Advisors. Plea ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...